Ceftriaxone‐associated biliary sludge and pseudocholelithiasis during childhood: A prospective study

Bör, Özcan; Dinleyici, Ener Çağrı; Kebapçı, Mahmut; Aydoğdu, Sultan Durmuş

doi:10.1111/j.1328-0867.2004.01884.x

Cited by 64 publications

(49 citation statements)

References 15 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of ceftriaxone-associated biliary sludge was reported between 17-57.5% (Schaad et al 1988;Papadopoulou et al 1999;Palanduz et al 2000;Herek et al 2001;Bor et al 2004;Ozturk et al 2005). Higher rates were reported with higher doses of ceftriaxone in those studies (100 mg/kg/day vs 60-70 mg/kg/day).…”

Section: Discussionmentioning

confidence: 82%

Pseudolithiasis due to Ceftriaxone Treatment for Meningitis in Children: Report of 8 Cases

Araz¹,

Okan

Demırcı

et al. 2007

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 82%

Pseudolithiasis due to Ceftriaxone Treatment for Meningitis in Children: Report of 8 Cases

Araz¹,

Okan

Demırcı

et al. 2007

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…The mixture of ceftriaxone and calcium ion is known to have the potential to cause incompatibility, resulting in biliary sludge and pseudocholelithiasis; even death has been reported. [12][13][14][15][16][17] In the case of ozagrel-calcium, the ionic product was less than 25% of the K sp . That is, the SI was <1, indicating that the solution was unsaturated, and the presence of ozagrel-calcium salts is unlikely.…”

Section: Comparison Of the Ozagrel Sodium Preparationsmentioning

confidence: 99%

“…It is therefore suggested that the ozagrel sodium preparation is compatible with calcium-containing products in vitro. 12) The risk of in vivo interactions between ozagrel and calcium can be calculated as follows: The maximum ozagrel concentration was reported to be 1139.82 ng/mL in human plasma at the end of an intravenous administration of 80 mg of ozagrel over a period of 2 h. 18 , which is 3.0×10 5 times lower than the K sp for ozagrel-calcium salt, when the calcium ion concentration in the plasma is 1.25 mmol/L. The halflife of ozagrel is short.…”

Section: Comparison Of the Ozagrel Sodium Preparationsmentioning

confidence: 99%

Prediction of Compatibility between Ozagrel Sodium Preparation for Injection and Calcium on the Basis of the Solubility Product

Tange

Yoshida

Hazekawa

et al. 2013

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

The purpose of the study was to evaluate the compatibility of ozagrel sodium solution and calciumcontaining transfusions using solubility product constants. We calculated the solubility product constant of mixtures of ozagrel sodium and calcium chloride and evaluated the compatibility of ozagrel sodium solution (both the original and generic products) with calcium chloride solution using a light obscuration particle counter. Various volumes of ozagrel solution were added to the calcium solutions to make final ozagrel concentrations of 0, 0.8, 1.6, 2.0, 2.4, 3.2 and 4.0 mmol/L. The solutions were gently agitated and stored at 25 and 40°C. The ozagrel concentration, calcium ion concentration and number of microparticles were measured. The solubility product constants obtained were 11.89×10 −9 mol 3 /L 3 (at 25°C) and 7.82×10 −9 mol 3 /L 3 (40°C). The number of insoluble microparticles was significantly increased when the ionic product was larger than the solubility product constant. In all ozagrel sodium products, the number of insoluble microparticles was within the allowable range according to the Japanese Pharmacopoeia. These results suggest that mixing ozagrel sodium with calcium-containing products is safe and without appreciable risk of incompatibility under clinical conditions.

show abstract

“…Bu yüzden "psödolitiyaz" olarak da adland›r›l-maktad›r (14)(15). Yap›lan çal›flmalarda seftriyakson tedavisi verilen çocuklarda yaklafl›k %25-30 oran›nda safra tafl› geliflti¤i ve tedavi kesildikten sonra k›sa sürede tafllar›n kendili¤inden kayboldu¤u bildirilmifltir (15)(16)(17). Çal›flmam›z-da hastalar›m›z›n 15'inde (%25) seftriyakson kullan›m› mevcuttu ve izlemde tafllar›n kayboldu¤u görülmüfltü.…”

unclassified

Çocukluk çağında safra taşları: 60 olgunun geriye dönük incelenmesi

Fakirullahoğlu¹,

Dinler²,

Kalaycı³

2011

tpa

View full text Add to dashboard Cite

Ç Ço oc cu uk kl lu uk k ç ça a¤ ¤› ›n nd da a s sa af fr ra a t ta afl fll la ar r› ›: : 6 60 0 o ol lg gu un nu un n g ge er ri iy ye e d dö ön nü ük k i in nc ce el le en nm me es si i G Ga al ll ls st to on ne es s i in n c ch hi il ld dh ho oo od d: : R Re et tr ro os sp pe ec ct ti iv ve e a an na al ly ys si is s o of f 6 60 0 c ca as se es s F Fa at ti ih h F Fa ak ki ir ru ul ll la ah ho o¤ ¤l lu u, , G Gö ön nü ül l D Di in nl le er r* *, , A Ay yh ha an n G Ga az zi i K Ka al la ay yc c› ›* * S Su um mm ma ar ry yAim: The purpose of this study was to documentation of the characteristics of children with cholelithiasis by means of age, sex, clinical manifestations and risk factors. Material and Method: Sixty cases (aged 0-18 years) with ultrasonographic evidence of cholelithiasis were enrolled in the study. Results: Mean age of the patients was 7.8±5.1 years (range: 0.25-18 years), 38 (63.3%) of them were females. Underlying risk factors were identified in 34 (56.7%) of cases (15 ceftriaxone use, six hemolytic diseases, five Down's syndrome, four obesity, two total parenteral nutrition and sepsis, one inflammatory disease and one chronic cholestatic liver disease). No etiology could be found in 26 (43.3%) patients who were defined as idiopathic. Of 46 patients who were followed at least for three months, eight (17.4%) had cholecystectomy, 16 (34.8%) showed differences in stone size and the stones were resolved in 24 patients (52.2%). When the cases related to ceftriaxone use were excluded, the percentage of the disappaerance of the stones was found to be 28.3%. Ursodeoxycolic acid was effective on resolution of symptoms in 69.2% of patients. The complications of gallstones were recorded in five (8.3%) patients. Conclusions: Cholelithiasis is more common in children than previously thought. The most common risk factors are ceftriaxone use and hemolytic diseases but about half of the cases are still idiopathic. There is a need for close monitoring of patients in especially risk groups because of gallstone development and its complications. (Turk Arch Ped 2010; 45: 119-23)

show abstract

Ceftriaxone‐associated biliary sludge and pseudocholelithiasis during childhood: A prospective study

Abstract: Reversible biliary sludge or pseudocholelithiasis due to ceftriaxone treatment is not a rare condition. Therefore it is benign, spontaneously resolved and clinical signs are usually absent.

Cited by 64 publications

References 15 publications

Pseudolithiasis due to Ceftriaxone Treatment for Meningitis in Children: Report of 8 Cases

Pseudolithiasis due to Ceftriaxone Treatment for Meningitis in Children: Report of 8 Cases

Prediction of Compatibility between Ozagrel Sodium Preparation for Injection and Calcium on the Basis of the Solubility Product

Çocukluk çağında safra taşları: 60 olgunun geriye dönük incelenmesi

Contact Info

Product

Resources

About